Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
Athenex, Inc.January 5, 2021 GMT
BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39th annual J. P. Morgan Healthcare Conference. Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development, will present a corporate overview at the conference.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic .
Athenex, Inc.December 15, 2020 GMT
Klisyri
is the first FDA approved proprietary product for Athenex
First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course
Klisyri will be manufactured by Athenex
Almirall will launch Klisyri in the U.S. in first quarter 2021
BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp. Klisyri is the first FDA
is the first FDA approved proprietary product for Athenex
First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course
Klisyri will be manufactured by Athenex
Almirall will launch Klisyri in the U.S. in first quarter 2021
BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp. Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall in the U.S. during the first quarter of 2021. Klisyri will be manufactured by Athenex, highlighting the vertically integrated cap
Edison, NJ (SBWIRE) 12/15/2020 Peer to Peer Insurance Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Peer to Peer Insurance industry with an attention on the Global market. The report gives key insights available status of the Peer to Peer Insurance producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Peer to Peer Insurance Market covering extremely significant parameters.
Key Players in This Report Include,